Alteration of B-cell subsets enhances neuroinvasion in mouse scrapie infection by von Poser-Klein, C et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Alteration of B-cell subsets enhances neuroinvasion in mouse
scrapie infection
von Poser-Klein, C; Flechsig, E; Hoffmann, T; Schwarz, P; Harms, H; Bujdoso, R;
Aguzzi, A; Klein, M A
von Poser-Klein, C; Flechsig, E; Hoffmann, T; Schwarz, P; Harms, H; Bujdoso, R; Aguzzi, A; Klein, M A (2008).
Alteration of B-cell subsets enhances neuroinvasion in mouse scrapie infection. Journal of Virology,
82(7):3791-3795.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Virology 2008, 82(7):3791-3795.
von Poser-Klein, C; Flechsig, E; Hoffmann, T; Schwarz, P; Harms, H; Bujdoso, R; Aguzzi, A; Klein, M A (2008).
Alteration of B-cell subsets enhances neuroinvasion in mouse scrapie infection. Journal of Virology,
82(7):3791-3795.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Virology 2008, 82(7):3791-3795.
Alteration of B-cell subsets enhances neuroinvasion in mouse
scrapie infection
Abstract
Acquired forms of prion diseases or transmissible spongiform encephalopathies are believed to occur
following peripheral exposure. Prions initially accumulate in the lymphoid system before spreading to
the nervous system, but the underlying mechanisms for prion transfer between the two systems are still
elusive. Here we show that ablation of the B-cell-specific transmembrane protein CD19, a coreceptor of
the complement system, results in an acceleration of prion neuroinvasion. This appears to be due to an
alteration of the follicular dendritic cell (FDC) network within the lymphoid tissue, thereby reducing the
distance between FDCs and adjacent nerve fibers that mediate prion neuroinvasion.
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Acquired forms of prion diseases or transmissible spongiform encephalopathies are believed to occur
following peripheral exposure. Prions initially accumulate in the lymphoid system before spreading to the
nervous system, but the underlying mechanisms for prion transfer between the two systems are still elusive.
Here we show that ablation of the B-cell-specific transmembrane protein CD19, a coreceptor of the complement
system, results in an acceleration of prion neuroinvasion. This appears to be due to an alteration of the
follicular dendritic cell (FDC) network within the lymphoid tissue, thereby reducing the distance between FDCs
and adjacent nerve fibers that mediate prion neuroinvasion.
Although prion infections are likely to be acquired orally,
animal studies have shown that peripheral infection with pri-
ons may occur by a variety of routes (17). These studies have
shown that following peripheral inoculation, most prion strains
accumulate in the lymphoreticular system. The site for accu-
mulation of prion infectivity and the disease-associated pro-
tein, designated PrPSc, during the lymphoreticular phase is the
follicular dendritic cell (FDC) network within germinal centers
of lymphoid tissue (16, 19). Following accumulation within
lymphoid tissue, prions migrate along peripheral nerves to the
brain, presumably via the spinal cord (7, 10, 11) or the vagus
nerve (2).
The function of FDCs in peripheral prion pathogenesis is
regulated in part by B cells, which provide growth and differ-
entiation factors for the stroma-derived cells (1, 6). B cells can
be divided into two phenotypically and functionally distinct
populations, referred to as B-1 cells (Ly-1) and conventional B
cells (B-2) (8, 13). B-1 cells are in a more activated state than
B-2 cells (28) and are a major source of antibody production
(29).
Signal transduction through a B-cell receptor primarily de-
termines the fate and function of B cells and is regulated by
other cell surface receptors such as the CD19/CD21 complex,
which serves as a positive regulator for an immune response
(21). In contrast, negative regulators such as CD22 are crucial
for terminating B-cell-receptor signal transduction to avoid
improper immune response against self-antigens (21). These
coreceptor-mediated B-cell immune regulatory functions may
also extend to an effect upon the FDC network. To test this
hypothesis, we investigated prion pathogenesis in mice that
lacked either CD19 or CD22. Since CD19/ mice (24) have a
decreased number of B-1 cells whereas CD22/ mice (20)
contain fewer B-2 cells, we reasoned that these experiments
would also address the role of different B-cell subsets in pe-
ripheral prion pathogenesis.
Following intracerebral challenge of mice with either a low
dose (3  103.1 50% lethal doses [LD50]) or a high dose (3 
106.1 LD50) of RML prions, the incubation times to terminal
prion disease were similar in wild-type, CD19/, and
CD22/ mice (Fig. 1A and B). Surprisingly, the absence of
CD19 resulted in a reduced incubation time after peripheral
exposure to RML prions which was independent of the in-
jected dose. CD19/ mice developed terminal disease in a
significantly shorter incubation time than did control mice
(129Sv) after intraperitoneal (i.p.) inoculation with either a
high dose (176 4 days versus 201 5 days [mean standard
deviation]; n  7, P  0.0005 [where n  number of mice per
group]) or a low dose (212  5 days [n  10] versus 246  7
days [n 8], P 0.0003) (Fig. 1D). In contrast, CD22/ mice
showed an incubation time similar to that seen with control
mice (C57BL/6) after i.p. challenge with either a high dose
(199  5 days [n  9] versus 196  4 days [n  7]) or a low
dose (235  7 days [n  10] versus 239  5 days [n  8]) (Fig.
1C). Regardless of the difference in latency upon infection with
a low dose, prion titers (Table 1) and histopathological changes
in the brains of CD19/ and CD22/ mice at the terminal
stage of the disease were similar to those found in wild-type
controls (data not shown).
To get further insights into the peripheral pathogenesis,
spleens of terminally sick CD19/, CD22/, and wild-type
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mice were analyzed for prion infectivity, level, and distribution
of PrPSc. Titers in spleens were similar, approximately 6 log
LD50 units per ml of 10% homogenates (Table 1), as calcu-
lated by the incubation time method (5). Comparable levels of
PrPSc (Fig. 2A) and similar distributions of PrPSc associated
with the FDC networks (Fig. 2B) were found in samples of all
the genotypes, as judged by Western blotting and histoblot
analysis (26), respectively. Furthermore, the prion titers during
the disease progression (at days 34 and 90) were determined by
a bioassay (5) of different splenic cell fractions (B cells, T cells,
non-B/T cells, and a stromal fraction) isolated by magnetically
activated cell sorting as previously described (23). Again, sim-
ilar levels of prion infectivity were found in cell fractions from
CD19/ and wild-type mice. These findings imply that the
reduced incubation time in CD19/ mice was not the result of
an increased accumulation of prions within either the spleen
lymphoid cell fraction or the FDC-containing stromal fraction.
To search for alterations in the microarchitecture of the
lymphoid organs responsible for the shorter incubation time of
prion disease in CD19/ mice, spleen sections were analyzed
by immunostaining. Neither the number of T cells stained with
either anti-CD4 or anti-CD8 antibodies nor the distribution of
B cells stained with either anti-CD45R or peanut agglutinin
was altered in comparison to that in the wild-type mice (data
not shown). Moreover, the numbers of FDC networks in the
spleen assessed with antibodies against FDC-M1 and CD21/
CD35 appeared to be similar (data not shown), and morpho-
metric measurements revealed similar numbers of FDC net-
works in spleen sections of CD19/, CD22/, and wild-type
(129Sv) mice (Fig. 3C).
Surprisingly, the FDC networks within the white pulp of
spleens of CD19/ mice seem to be altered with respect to
the distance between the FDC networks and innervating nerve
fibers visualized by double labeling against CD21/CD35 and
tyrosine hydroxylase (THL), respectively. As shown in Fig. 3A,
the distance between the FDC network and the dense plexuses
of nerve fibers surrounding the central arterioles in spleen
sections from CD19/ mice was reduced compared to that
seen in CD22/ and wild-type (129Sv) mice. However, the
typical localization and organization of FDC networks and
nerve fibers within the lymphoid follicles from all three lines
are unaltered (Fig. 3A). Moreover, the total amount of THL in
the spleens of CD19/ mice seems to be no higher than that
in CD22/ and wild-type mice, as determined by Western
blotting (data not shown), excluding the possibility that the
shorter latency of CD19/ mice to peripheral exposure is due
to hyperinnervation of the lymphoid organs by sympathetic
nerves, as recently shown (7, 10, 11). In order to measure the
FIG. 1. Latency of prion disease in CD19/, CD22/, and wild-type mice. (A and B) No difference in the incubation time of CD19/ (B) and
CD22/ mice (A) was found after intracerebral inoculation with RML prions, in comparison to that of wild-type mice on the same genetic
background. (C and D) After i.p. inoculation, CD22/ mice (C) developed prion disease with an incubation time similar to that of wild-type mice
regardless of the dose applied, whereas CD19/ mice (D) showed a significant reduction in the incubation time with both a high dose (P 0.0005
by log rank test) and a low dose (P  0.0003) of RML prions. The dose of inoculum, the incubation time (mean number of days  standard
deviation), and the number (n) of infected/number of diseased mice per group are indicated in the survival curves.
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altered distance between the FDC networks and nerve fibers in
the spleens of CD19/ mice, a morphometric analysis was
performed by measuring this distance in follicles of spleen
sections from three uninfected mice of each genotype. A re-
duction of more than 50% in this distance was found in
CD19/ mice, compared to CD22/ and wild-type mice
(129Sv) (Fig. 3B). These data suggest that the reduced incu-
bation time of disease in CD19/ mice after peripheral ap-
plication of prions is most likely related to the reduced distance
between the FDC networks and innervating peripheral nerve
fibers, which enables prions to be rapidly transported to the
peripheral nervous system.
The conclusion reached in this study that closeness of the
FDC network and the peripheral nervous system in CD19/
mice may allow a more efficient migration of prions between
the two sites is supported by a recent study showing that po-
sitioning of the FDCs within the spleen affects prion neuroin-
vasion (22). However, the accelerated response of these mice is
observed only after peripheral challenge with a low dose of
infectivity (22), whereas CD19/ mice display a shorter incu-
bation time after peripheral infection with either a high or a
low dose of RML prions. This implies that additional factors
may contribute to the phenotype described here. The activity
of CD19 often relies on its association with molecules such as
CD21 (4) and others (3). Therefore, the loss of CD19 may
disturb B-cell activation and function, which, if it exists, may be
mediated through the complement system that has been shown
FIG. 2. Accumulation of PrPSc in spleens of terminally ill mice after i.p.
challenge with RML prions. (A) Western blot analysis of splenic tissue (80
g) from CD19/ and CD22/mice and corresponding wild-type controls
shows similar levels of proteinase K (PK)-resistant PrPSc at the indicated days
postinoculation (dpi) and independent of the dose (LD50) given. Signals for
PrP were detected with the polyclonal anti-PrP serum SA2124. , no PK
treatment; , PK treatment. (B) Histoblot analysis of splenic sections from
CD19/, CD22/, and wild-type (129Sv) mice following i.p. inoculation
with a low dose shows similar distributions of PrPSc associated with the FDC
networks when treated with PK. No PrP signal was detectable in noninfected
tissue of wild-type mice [129Sv(no)].
TABLE 1. Prion infectivity in spleen cell fractions, total spleens, and brains of mice after i.p. challenge with a low dose of RML prions
Mouse group Fraction (%)a Primary incubationtimeb (dpi)
Bioassay result in indicator mice
No. of diseased mice/
no. of infected mice
No. of days of incubation
to terminal prion diseasec Prion titer
d
Wild-type (129Sv) B cells 34 3/3 103  12 3.2
90 4/4 91  6 3.7
T cells 34 4/4 99  5 3.4
90 4/4 92  7 3.7
Non-B/T cells 34 0/4 160 1.5
90 1/4 135, 160 1.5
Spleen cells 34 4/4 94  5 3.6
90 4/4 91  8 3.7
Stroma (1) 34 4/4 95  7 5.1
90 3/3 83  5 5.7
Spleen (1) 238 3/3 83  4 5.7
244 4/4 79  7 6.0
Brain (1) 238 4/4 62  4 7.7
244 4/4 56  3 8.5
CD19/ B cells 34 4/4 92  9 3.7
90 4/4 84  5 4.2
T cells 34 4/4 95  6 3.5
90 4/4 98  7 3.4
Non-B/T cells 34 0/4 160 1.5
90 2/4 112, 124, 160 1.5
Spleen cells 34 0/4 91  4 3.7
90 2/4 85  5 4.1
Stroma (1) 34 4/4 91  4 5.3
90 4/4 85  5 5.6
Spleen (1) 203 4/4 90  5 5.3
206 3/3 81  7 5.8
Brain (1) 203 3/3 60  4 7.9
206 3/3 64  7 7.4
CD22/ Spleen (1) 233 3/3 78  6 6.1
247 4/4 79  7 6.0
Brain (1) 233 4/4 61  5 7.8
247 4/4 56  4 8.5
a Values in parentheses indicate the percent homogenate used for the bioassay.
b The primary incubation time is the day postinoculation when the tissue was used for the bioassay.
c The number of days to terminal prion disease is given as the mean  the standard deviation unless not all mice succumbed to the disease during the time period
they were observed; in those cases, each value given is the number of days for each individual mouse.
d Titers were calculated by the incubation time method (5) and are given in log LD50 units per milliliter of 10% homogenate or 106 cells.
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to facilitate neuroinvasion of prions (12, 15). Since CD19 rep-
resents a costimulatory molecule of the complement systems, it
is possible that compensatory mechanisms are up-regulated in
the absence of CD19, thereby facilitating neuroinvasion of
prions. However, prion titers in the spleens of prion-infected
CD19/ mice were similar to those found in controls, exclud-
ing the possibility that the intrinsic capacity of the spleen to
retain and replicate prions is altered in CD19/ mice (Table
1). FDCs may retain prions indirectly through interactions
between C3 and CD21/CD35 or between C1q and C1q recep-
tor, thereby bridging the gap between FDCs and peripheral
nerves (16, 19). In line with this idea, the reduced incubation
time of CD19/ mice after peripheral challenge is the conse-
quence of the shorter distance between FDCs and peripheral
nerves and the compensatory activity of the complement sys-
tem due to loss of CD19 on B cells.
Alternatively, significant effects on prion pathogenesis may
be expected if aberrant signaling in mice devoid of CD19 leads
to modulation of the cytokine response by B cells, as suggested
by Matsushita et al. (18). Various cytokines have been shown
to have an effect on the development of prion disease (27).
Since mice devoid of CD19 developed a Th1 cytokine bias with
reduced production of Th2 cytokines such as interleukin-10
(18), it is possible that the accelerated response of CD19/
mice to peripherally applied prions may due to the loss of
anti-inflammatory cytokines, rather than a direct effect of loss
of CD19 function. Indeed, certain inflammatory conditions are
associated with an increase in the spread of prions within the
host (14, 25). PrPSc deposition in these inflamed areas is asso-
ciated with up-regulation of lymphotoxin and induction of
FDCs (9). However, the number of FDC networks in mice
devoid of CD19 was not altered (Fig. 3C).
The findings reported here support the notion that the dis-
tance between the FDC network and the adjacent peripheral
nerves contributes to the neuroinvasion of prions. However,
additional mechanisms might be involved in this process, which
are still unknown in the understanding of peripheral prion
pathogenesis.
We thank Nele Lindner for her excellent technical assistance.
This study was supported by the Bavarian research cooperation for
prions (FORPRION), by the German Research Foundation (SFB 479,
TP-C9), by the Federal Ministry of Education and Research (BMBF,
FKZ: 01KO0516), and by funds from the Biotechnology and Biological
Sciences Research Council (BBSRC). E.F. is supported by the Emmy
Noether-Programm of the German Research Foundation.
REFERENCES
1. Aguzzi, A., and M. Heikenwalder. 2005. Prions, cytokines, and chemokines:
a meeting in lymphoid organs. Immunity 22:145–154.
2. Beekes, M., P. A. McBride, and E. Baldauf. 1998. Cerebral targeting indi-
cates vagal spread of infection in hamsters fed with scrapie. J. Gen. Virol.
79:601–607.
3. Bradbury, L. E., G. S. Kansas, S. Levy, R. L. Evans, and T. F. Tedder. 1992.
The CD19/CD21 signal transducing complex of human B lymphocytes in-
FIG. 3. Location and distance of FDC networks and nerve fibers in spleens of noninfected mice. (A) Immunofluorescent staining for FDCs with
CD21/CD35 (green) and nerve fibers with THL (red) shows that the distance between the FDC network and nerve fibers associated with B-cell
follicles in the spleens of CD19/ mice is reduced compared to that of CD22/ and wild-type control mice. Scale bar, 100 m. (B) Quantification
of the distance between the FDC networks and adjacent nerve fibers in splenic follicles of three mice for each group is shown as individual dots,
and mean values are shown as bars. The mean values were 88 15 m (n 25) for CD19/ mice compared to 185 33 m (n 23) for CD22/
mice and 198  43 m (n  20) for wild-type (129Sv) mice. (C) Quantitative analysis of FDC networks in spleens of CD19/, CD22/, and
wild-type (129Sv) mice show no difference in total number of CD21/CD35-positive FDC networks. Data represent the number of FDC networks
per mm2 (mean  standard deviation) in serial sections (n  7) from three mice of each genotype analyzed.
3794 NOTES J. VIROL.
 at UNIVERSITATSSPITAL on August 21, 2008 
jvi.asm.org
D
ow
nloaded from
 
cludes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Im-
munol. 149:2841–2850.
4. Del Nagro, C. J., D. C. Otero, A. N. Anzelon, S. A. Omori, R. V. Kolla, and
R. C. Rickert. 2005. CD19 function in central and peripheral B-cell devel-
opment. Immunol. Res. 31:119–131.
5. Fischer, M., T. Ru¨licke, A. Raeber, A. Sailer, M. Moser, B. Oesch, S. Brand-
ner, A. Aguzzi, and C. Weissmann. 1996. Prion protein (PrP) with amino-
proximal deletions restoring susceptibility of PrP knockout mice to scrapie.
EMBO J. 15:1255–1264.
6. Fu, Y.-X., G. Huang, Y. Wang, and D. D. Chaplin. 1998. B lymphocytes
induce the formation of follicular dendritic cell clusters in a lymphotoxin
alpha-dependent fashion. J. Exp. Med. 187:1009–1018.
7. Glatzel, M., F. L. Heppner, K. M. Albers, and A. Aguzzi. 2001. Sympathetic
innervation of lymphoreticular organs is rate limiting for prion neuroinva-
sion. Neuron 31:25–34.
8. Hardy, R. R., and K. Hayakawa. 2001. B cell development pathways. Annu.
Rev. Immunol. 19:595–621.
9. Heikenwalder, M., N. Zeller, H. Seeger, M. Prinz, P. C. Klohn, P. Schwarz,
N. H. Ruddle, C. Weissmann, and A. Aguzzi. 2005. Chronic lymphocytic
inflammation specifies the organ tropism of prions. Science 307:1107–1110.
10. Kimberlin, R. H., and C. A. Walker. 1988. Incubation periods in six models
of intraperitoneally injected scrapie depend mainly on the dynamics of agent
replication within the nervous system and not the lymphoreticular system.
J. Gen. Virol. 69:2953–2960.
11. Kimberlin, R. H., and C. A. Walker. 1980. Pathogenesis of mouse scrapie:
evidence for neural spread of infection to the CNS. J. Gen. Virol. 51:183–
187.
12. Klein, M. A., P. S. Kaeser, P. Schwarz, H. Weyd, I. Xenarios, R. M. Zink-
ernagel, M. C. Carroll, J. S. Verbeek, M. Botto, M. J. Walport, H. Molina, U.
Kalinke, H. Acha-Orbea, and A. Aguzzi. 2001. Complement facilitates early
prion pathogenesis. Nat. Med. 7:488–492.
13. Lam, K. P., and K. Rajewsky. 1999. B cell antigen receptor specificity and
surface density together determine B-1 versus B-2 cell development. J. Exp.
Med. 190:471–477.
14. Ligios, C., C. J. Sigurdson, C. Santucciu, G. Carcassola, G. Manco, M.
Basagni, C. Maestrale, M. G. Cancedda, L. Madau, and A. Aguzzi. 2005.
PrPSc in mammary glands of sheep affected by scrapie and mastitis. Nat.
Med. 11:1137–1138.
15. Mabbott, N. A., M. E. Bruce, M. Botto, M. J. Walport, and M. B. Pepys. 2001.
Temporary depletion of complement component C3 or genetic deficiency of
C1q significantly delays onset of scrapie. Nat. Med. 7:485–487.
16. Mabbott, N. A., F. Mackay, F. Minns, and M. E. Bruce. 2000. Temporary
inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat.
Med. 6:719–720.
17. Mabbott, N. A., and G. G. MacPherson. 2006. Prions and their lethal journey
to the brain. Nat. Rev. Microbiol. 4:201–211.
18. Matsushita, T., M. Fujimoto, M. Hasegawa, K. Komura, K. Takehara, T. F.
Tedder, and S. Sato. 2006. Inhibitory role of CD19 in the progression of
experimental autoimmune encephalomyelitis by regulating cytokine re-
sponse. Am. J. Pathol. 168:812–821.
19. Montrasio, F., R. Frigg, M. Glatzel, M. A. Klein, F. Mackay, A. Aguzzi, and
C. Weissmann. 2000. Impaired prion replication in spleens of mice lacking
functional follicular dendritic cells. Science 288:1257–1259.
20. O’Keefe, T. L., G. T. Williams, S. L. Davies, and M. S. Neuberger. 1996.
Hyperresponsive B cells in CD22-deficient mice. Science 274:798–801.
21. Poe, J. C., M. Hasegawa, and T. F. Tedder. 2001. CD19, CD21, and CD22:
multifaceted response regulators of B lymphocyte signal transduction. Int.
Rev. Immunol. 20:739–762.
22. Prinz, M., M. Heikenwalder, T. Junt, P. Schwarz, M. Glatzel, F. L. Heppner,
Y. X. Fu, M. Lipp, and A. Aguzzi. 2003. Positioning of follicular dendritic
cells within the spleen controls prion neuroinvasion. Nature 425:957–962.
23. Raeber, A. J., M. A. Klein, R. Frigg, E. Flechsig, A. Aguzzi, and C. Weiss-
mann. 1999. PrP-dependent association of prions with splenic but not cir-
culating lymphocytes of scrapie-infected mice. EMBO J. 18:2702–2706.
24. Rickert, R. C., K. Rajewsky, and J. Roes. 1995. Impairment of T-cell-depen-
dent B-cell responses and B-1 cell development in CD19-deficient mice.
Nature 376:352–355.
25. Seeger, H., M. Heikenwalder, N. Zeller, J. Kranich, P. Schwarz, A. Gaspert,
B. Seifert, G. Miele, and A. Aguzzi. 2005. Coincident scrapie infection and
nephritis lead to urinary prion excretion. Science 310:324–326.
26. Taraboulos, A., K. Jendroska, D. Serban, S. L. Yang, S. J. DeArmond, and
S. B. Prusiner. 1992. Regional mapping of prion proteins in brain. Proc.
Natl. Acad. Sci. USA 89:7620–7624.
27. Thackray, A. M., A. N. McKenzie, M. A. Klein, A. Lauder, and R. Bujdoso.
2004. Accelerated prion disease in the absence of interleukin-10. J. Virol.
78:13697–13707.
28. Tuscano, J. M., G. S. Harris, and T. F. Tedder. 2003. B lymphocytes con-
tribute to autoimmune disease pathogenesis: current trends and clinical
implications. Autoimmun Rev. 2:101–108.
29. Wang, Y., and R. H. Carter. 2005. CD19 regulates B cell maturation, pro-
liferation, and positive selection in the FDC zone of murine splenic germinal
centers. Immunity 22:749–761.
VOL. 82, 2008 NOTES 3795
 at UNIVERSITATSSPITAL on August 21, 2008 
jvi.asm.org
D
ow
nloaded from
 
